Maze Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference Life Science Investing
NRx Pharmaceuticals and neurocare Group AG Announce Joint Offering of Neuroplastic Therapy Targeting Depression, PTSD, and other mental health afflictions Life Science Investing
Innovotech Inc. Announces Amalgamation of Subsidiaries to Streamline Operations Life Science Investing
Axsome Therapeutics Announces FDA Acceptance and Priority Review of Supplemental New Drug Application for AXS-05 for the Treatment of Alzheimer's Disease Agitation Life Science Investing
BioAtla and GATC Health Announce a $40 Million Special Purpose Vehicle Transaction to Advance Ozuriftamab Vedotin into a Registrational Trial for 2L+ Oropharyngeal Squamous Cell Carcinoma Life Science Investing
Axsome Therapeutics Announces FDA Pre-NDA Meeting Minutes for AXS-12 in Narcolepsy Supporting NDA Submission Life Science Investing
